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     Abstract 
We examined whether the APOE 4 allele was associated with cognitive benefits in young 
adulthood but reversed to confer cognitive deficits in later life (“antagonistic pleiotropy”) in 
the absence of dementia-related neuropathology. We also tested whether the 2 allele was 
associated with disadvantages in early adulthood but offered protection against cognitive 
decline in early old age. Eight-year cognitive change was assessed in 2,013 cognitively-
normal community-dwelling adults aged either 20 to 24, 40 to 44, or 60 to 64 years at 
baseline. Although cognitive decline was associated with age, multilevel models contrasting 
the 2 and 4 alleles provided no evidence that APOE genotype was related to cognitive 
change in any of the age groups. The findings suggest that in the absence of clinically salient 
dementia pathology, APOE 2 and 4 alleles do not exhibit antagonistic pleiotropy in relation 
to cognition between the ages of 20 and 72 years. 
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Does APOE genotype influence the trajectory of cognitive change across the adult lifespan? 
Importantly, does APOE-related variation in cognition over time occur in the absence of the 
neuropathology associated with dementia? These pressing questions provided the motivation 
for the present study. APOE genotype is determined by three alleles, 2, 3 and 4, resulting 
in six possible combinations (2/2, 2/3, 2/4, 3/3, 3/4, 4/4). While possession of the 4 
allele is an established risk factor for dementia (1) and 2 offers protection against the disease 
(2), the association between APOE genotype and cognition across the adult lifespan is less 
clear.  
A major question concerns whether APOE 4 produces a cognitive phenotype (3) in that the 
allele directly influences cognition, or whether 4-related cognitive deficits reflect the 
preclinical phase of, as yet, undetected dementia and therefore represent an early behavioral 
marker in persons genetically predisposed to the disease. Meta-analyses (4, 5) suggest the 
former. However, it is unclear how many of the studies contributing to these analyses 
included individuals in the prodromal phase of dementia. Longitudinal studies produce mixed 
findings, some suggesting that there is little 4-related change in cognitive or mental ability in 
older adults (6-9), while others suggest greater decline in 4 carriers (10-15). However, 
although some of these latter investigations have made some formal attempt to rule out sub-
clinical dementia cases (11, 13, 15), in others it is not clear whether 4-related cognitive 
decline is due to the undetected disease. Recent research identifying an association between 
the 4 allele and mild cognitive impairment (16), widely held to reflect the subclinical phase 
of dementia, underlines this point. 
Against this background, the first major objective of the present investigation, therefore, was 
to assess 8-year cognitive change as a function of APOE genotype in older cognitively-
normal adults who at baseline were aged 60 to 64 years. In order to ensure a cognitively 
healthy sample, we excluded persons with a variety of neurological disorders from the 
sample. Our particular interest was whether 4 carriers exhibited more precipitous cognitive 
decline in this older cognitively intact group. 
The second major concern of this study related to the association between APOE genotype 
and cognition across the adult lifespan. A recent proposal, with its origins in evolutionary 
theory (17), holds that this association is an example of “antagonistic pleiotropy” where 
advantages in early life are offset by a greater vulnerability to disease in later life (18). 
Consistent with this suggestion, several studies have shown better cognitive performance in 
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young 4-carrying adults compared to those without the 4 allele (19-21). However, evidence 
against the hypothesis was reported by two cross-sectional studies in the present population 
(22, 23). Indeed, Bunce and colleagues (22) specifically tested this hypothesis in over 5,000 
participants and found no evidence of 4-related cognitive benefits in young adulthood or 
middle age.  
Interestingly, it is also suggested that the reverse association may exist in relation to the 2 
allele (24). That is, possession of the 2 allele may be associated with disadvantages in early 
life, cognitive and otherwise, but confer greater protection against cognitive decline and 
neuropathology in later life. In old age, the protective effect of the 2 allele is widely 
recognized (e.g., Ref 2). Regarding the hypothesized detrimental effect in early life, Bloss 
and colleagues (24) reported visuospatial deficits in 2-carrying children and adolescents 
relative to their 3- and 4-carrying age cohort and there is also work suggesting that 2 
carriers are over-represented in perinatal deaths (25). Although there is little empirical 
evidence, these studies are consistent with the idea that the 2 allele may be associated with 
disadvantages in early life. Conversely, there is evidence that the 2 allele confers protection 
in extreme old age (e.g., Ref 26). 
Currently, our understanding of the association between APOE genotype and cognition across 
the lifespan is incomplete. There is a need for work that not only assesses the trajectory of 
cognitive change as a function of APOE in early old age, but also in young adulthood and 
midlife. Such work will provide important insights into what is potentially a major 
determinant of cognitive aging. Therefore, in addition to investigation of the association 
between APOE and cognitive change in older adults, we also assessed 8-year cognitive 
change in young and middle-aged adults aged, respectively, 20 to 24, and 40 to 44, years at 
baseline. Uniquely, we focused our main analyses on persons possessing either the 2 or 4 
alleles while excluding those with the 3/3 genotype, held to be of neutral influence. In this 
way, our intention was to provide the most robust test of the opposing influences of the 2 
and 4 alleles in the various age groups. The hypotheses we tested was that in older adults, 
relative to those possessing the 2 allele, 4 carriers would exhibit more precipitous cognitive 
decline. By contrast, in the younger age cohort, any initial 4-related cognitive benefits 
relative to 2 were expected to attenuate over time. As the middle-age cohort represent the 
hypothesized crossover point for the opposing genetic influences (18), we did not expect any 
differences in cognitive performance according to APOE genotype.  
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In order to robustly test these associations over time, we directly contrasted the opposing 
influences of the 2 and 4 alleles on cognitive change in 2,013 community-dwelling adults 
across several domains including processing speed, working memory, lexical decision 
making and episodic memory. Recent meta-analyses (4, 5) suggest that cognitive tasks 
placing demands on processing speed, executive function or episodic memory, are 
particularly sensitive to APOE 4 effects. 
Method 
Participants 
Data were drawn from the Personality and Total Health (PATH) Through Life Project, a 
longitudinal population-based study of age, mental health and cognition. The study 
background and procedures for testing have been described in detail elsewhere (27). 
Participants resided in Canberra or nearby Queanbeyan, and were recruited through electoral 
rolls, registration for which is compulsory for Australian citizens.  Here, three waves of data 
were used, measured at 4-year intervals over 8 years. At baseline, the number of participants 
who returned the survey was 7,485, of whom 2,404 were aged 20 to 24 years, 2,530 aged 40 
to 44 years and 2,551 60 to 64 years. In each age group, approximately half were female. 
There was limited sample attrition four (Wave 2 = 6,680) and eight (Wave 3 = 5,996) years 
later. Approval for the study was obtained from the Human Research Ethics Committee of 
the Australian National University. 
  
In the present study, there were various exclusions from the baseline sample of 7,485. 
Participants were removed who were either missing APOE data (n = 518) or, following 
earlier studies in this sample (22, 23), because they did not describe themselves as 
Caucasian/White (n = 407) as ethnic differences in the frequency of APOE genotype have 
been demonstrated. Earlier work (28) in this dataset suggest that the resulting allelic 
frequencies do not differ from other Caucasian populations. Additionally, participants were 
excluded if they reported stroke (n = 178), head injury (n = 827) or epilepsy (n = 51), and 
older participants scoring <24 on the Mini Mental State Examination (MMSE: 29) at any 
time point (n = 37). Although the multilevel modeling framework used in the statistical 
analyses permitted inclusion of all participants regardless of attrition, only participants with 
available baseline data for all the cognitive variables were included in analyses.  
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Provisional statistical analyses investigated all six APOE genotypes and age in relation to the 
cognitive measures over time (N = 5,384). However, as the major objective of this 
investigation was to directly contrast the opposing influences of the 2 and 4 alleles, the 
main statistical analyses involved a robust test of the relative influence of the two alleles. In 
order to increase statistical power, we combined persons with the 2/2 and 2/3 genotypes 
and contrasted them with participants of the 3/4 and 4/4 genotypes. Because of the 
opposing influence of the APOE 2 and 4 alleles, individuals possessing the 2/4 genotype 
were removed (n = 140) and individuals with 3/3 genotype were also excluded (n = 3,231) 
as this genotype is held to be neutral in its influence. Of the resulting 2,013 participants, 
55.0%, 53.4% and 50.3% were women for the 20s, 40s and 60s age cohorts, respectively. 
Mean years of education for the age groups were 14.63 (SD = 1.58), 14.62 (SD = 1.58) and 
14.68 (SD = 1.93) for the 20s, 40s and 60s, respectively. The mean length of time in study 
from baseline to Wave 3 was 8.05 years (SD = 0.27). The distribution of APOE genotype in 
this sample is presented in Table 1. A X2 test did not find APOE genotype to vary with age. 
Further information on attrition and scores according to age and APOE genotype across the 
waves are presented in Table 2.  
Cognitive measures 
A battery of tests was administered to participants covering a range of cognitive domains 
including processing speed, working memory, immediate and delayed recall and lexical 
decision making. This included the Symbol Digit Modalities Test (30) in which participants 
were given 90 s to indicate the appropriate symbol-digit pairings (by writing the number 
beneath the symbol), and a backward digit span test from the Wechsler Memory Scale in 
which participants repeated a list of three to seven digits backwards (31). Also, immediate 
and delayed recall was assessed using the first trial of the California Verbal Learning Test 
(32). This non-standard version of the task required participants to remember 16 items (e.g., 
chisel, tangerine, sweater, paprika) and to recall them immediately and again after a brief grip 
strength task (delayed recall). Finally, Lexical decision making was measured through the 
Spot-the-Word test (33) which is composed of 60 questions and required participants to 
indicate which of two items was a valid word. 
APOE genotyping 
At Wave 1, genomic DNA was extracted from buccal swabs using QIAGEN DNA Blood kits 
(#51162; QIAGEN, Hilden, Germany). Two single-nucleotide polymorphisms (SNPs; 
rs429358 and rs7412) were genotyped to identify APOE genotypes comprised of the APOE 
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2, 3 and 4 alleles using TaqMan assays (Applied Biosystems [ABI], Foster City, CA) as 
described elsewhere (23).  
Data preparation and statistical analysis 
To allow comparison across tasks, all cognitive scores across the three waves were converted 
into T-scores (M = 50, SD = 10) using the baseline means and standard deviations across age 
groups.  Data were analyzed using the Mixed procedure in SPSS version 18.0.2 (IBM 
Corporation, 2010). Age group and APOE genotype served as fixed time-invariant effects in 
the multi-level models.  Rather than using wave of measurement, time-in-study served as a 
time-varying fixed effect as not all participants were tested at precise 4-year intervals. The 
random effects for both the intercept and time-in-study took into account individual 
differences (within-person variation) in cognition over time. Models used an unstructured 
covariance matrix structure. Regarding the statistical analyses of primary interest, each 
cognitive variable was assessed initially using an intercept-only model to provide a baseline 
index of between- and within-person variation (Model 1). Next, in Model 2, we estimated 
whether significant change occurred in any of the cognitive measures over the three time 
points and whether this varied by age cohort. In the third model, we added APOE genotype. 
Importantly, our concern was whether the slopes varied according to APOE genotype within 
each of the age groups. Finally, we reran the models controlling for gender and education.  
Results 
The critical finding from the provisional multilevel models which included all six APOE 
genotypes was that for each of the cognitive variables, none of the main effects for APOE, or 
Age group x APOE genotype x Time interactions, were significant. This latter finding 
indicates that APOE genotype did not affect cognition over time within any of the age groups. 
In the main analyses that followed, therefore, the opposing effects of the 2 and 4 alleles 
were directly contrasted. Descriptive statistics for the cognitive variables as a function of age, 
APOE genotype and time are presented in Table 1. It can be seen that the number of 4 
carriers in the sample was substantially larger than for 2 carriers.  
     Table 1 and 2 about here 
Age group differences in intercept and slope 
Statistics for Models 1 and 2 are presented in Table 2. Adding age group in Model 2 
significantly improved model fit for all of the cognitive variables. Additionally, there were 
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significant age group differences in both the starting point and slope for the majority of 
variables. With one exception, the 20s group had the highest initial scores, followed by the 
40s and the 60s. For spot-the-word, the opposite was the case, with the 60s cohort recording 
the highest starting scores followed by the 40s and 20s groups. All age group intercept 
contrasts were significant with the exception of 60s versus 40s for backward digit span, and 
40s versus 20s for immediate recall.  
Regarding change over time, with each additional year, the average participant in the 60s 
group experienced significant decline in symbol digit, and immediate and delayed recall, but 
improved in spot-the-word performance. The trend for backward digit span was 
nonsignificant. The 20s group improved over time on all cognitive variables while the 40s 
group improved on backward digit span, spot-the-word and immediate recall. Between-group 
contrasts of the slopes suggested significant differences for all variables for 60s versus 20s 
groups, while for 60s versus 40s all contrasts were significant except for spot-the-word. 
Significant differences were also evident for all 40s versus 20s contrasts except for backward 
digit span.  
     Tables 3 and 4 about here 
Does APOE genotype influence the intercept and slope within each age group? 
The critical element of the analyses was the addition of APOE genotype in Model 3 (see 
Table 3). Three important findings emerged from this model. First, the addition of APOE did 
not improve overall model fit for any of the cognitive variables (df = 6, 2  ps>.25). Second, 
neither the Age x APOE interactions nor comparison of the slopes for 2 and 4 were 
significant, suggesting that APOE genotype did not modify the findings described in Model 
2. Finally and most importantly, for all of the cognitive variables, none of the nested 2 
versus 4 slope contrasts within any of the age cohorts were significant. This suggests that for 
cognitively normal young, middle-aged and older adults living in the community, neither the 
2 nor 4 alleles influenced cognitive change over the 8-year study period. Using symbol 
digit as an example, Figure 1 presents the predicted values for cognitive change as a function 
of age and APOE genotype. As can be seen, there is little evidence of genetic-related variance 
over time for any of the age groups. 
     Figure 1 about here 
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Additionally, we repeated the analyses while controlling for gender and education. The 
addition of these covariates did not affect the original findings in any way. Finally, we 
conducted a further test of the opposing effects of 2 and 4 by contrasting the 4/4 group 
with the 2/2 + 2/3 groups (i.e., 3/4 carriers were excluded). Although two of the models 
failed to converge (for spot-the-word and immediate recall) due to the small numbers of 
participants in the 4/4 group, the pattern of results was very similar to those from the earlier 
analyses. Importantly, APOE genotype did not modify either the intercepts or slopes for any 
of the cognitive variables.  
Discussion 
This investigation possesses several unique features. First, the research involved a large-scale 
population-based sample of over 2,000 persons aged either 20 to 24, 40 to 44, or 60 to 64, 
years at baseline. Second, we used multilevel modelling to directly contrast the opposing 
influences of the 2 and 4 alleles on cognitive change over an 8-year period in a range of 
cognitive domains including processing speed, working memory, lexical decision making and 
episodic memory. Additionally, we were careful to assess only cognitively normal 
individuals at baseline, excluding from the analyses individuals reporting neurological 
disorders, and in the older cohort, eliminating persons exhibiting deficits in global cognition 
that may serve as an early marker of dementia.  
Our findings were unequivocal. There was no evidence of cognitive change as a function of 
APOE genotype on any of the measures in any of the age groups. Even in analyses 
contrasting 4/4 carriers only, possession of the 4 allele was not associated with more 
precipitous cognitive decline in old age and neither was there any evidence of cognitive 
benefits in young adulthood relative to those with the 2 allele. Conversely, there was no 
evidence of 2-related disadvantages in young adults or benefits in the older cohort. Nor was 
there evidence of APOE-related cognitive change in midlife. Inclusion of the 3/3 genotype 
in provisional analyses did not alter these null findings as none of the APOE main effects or 
APOE x Time interactions involving this allele were significant. Moreover, taking gender 
into account did not alter any of these null findings. 
The findings have several implications for the potential influence of APOE genotype on 
cognition between the ages of 20 and 72 years. First, they strongly suggest that in old age, 
rather than representing a cognitive phenotype (3), 4-related cognitive deficits, where they 
are found, may reflect the preclinical phase of, as yet, undetected dementia. It is well-
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established that the prodromal phase of the disease precedes eventual diagnosis by several 
years. Indeed, one study (34) has reported cognitive deficits up to ten years in advance of 
clinical diagnosis, and histopathological studies (35, 36) suggest that the neuropathological 
hallmarks of dementia are present in early adulthood and middle age. As possession of the 4 
allele is a major risk factor for dementia, it is possible that 4-related cognitive decline 
commonly reported (e.g., Refs 10, 11-15) is associated with the subclinical phase of the 
disease, even though some studies (e.g., Refs 13, 15) removed persons with low global 
cognition scores. In the present study, we were also careful to eliminate from the analyses 
individuals with a range of neurological disorders and also low global cognition scores. 
Although we cannot rule out the possibility that participants will experience dementia in the 
future, we are cautiously confident that with those exclusions, the sample was cognitively 
normal. As with studies elsewhere that have taken possible or future dementia into account in 
relation to cognition (6-8) or the neuroanatomical structures supporting cognition (e.g., Refs 
37, 38), the present null findings add to evidence suggesting that 4-related cognitive deficits 
reflect the subclinical phase of undetected dementia. 
The findings also have important implications for the suggestion that 4-cognition relations 
represent an example of “antagonistic pleiotropy” (18) where possession of the 4 allele is 
associated with cognitive benefits in young adulthood, but reverses to become a risk factor 
for more marked cognitive decline in later life. Consistent with earlier cross-sectional studies 
in this sample (22, 23), we found no evidence of APOE genotype-related differences in 
cognitive performance over time in young or middle-aged cohorts. Equally, the suggestion 
that the reverse effect may exist in relation to the 2 allele (24) did not receive support. 
Indeed, the results indicate that unlike in extreme old age (e.g., Ref 26), the 2 allele does not 
moderate cognitive decline in early old age. The present study is one of the largest to test the 
hypothesis in young adults and those in midlife, and we believe the first to examine these 
issues longitudinally. Although pleiotropic associations involving the 4 allele may exist in 
other domains (e.g., Ref 39) and the 4 allele may be associated with various benefits such as 
high vitamin D status (40), our findings clearly suggest that claims of such an association 
specifically between the 4 allele and cognition across the ages represented in this study, or 
indeed the reverse association involving the 2 allele, should be treated with caution.  
There are some limitations to the study that we should acknowledge. The first is that although 
we did our best to ensure that participants included in the analyses were cognitively normal 
by excluding individuals with MMSE scores <24, it is still possible that in using this 
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measure, persons in the preclinical phase of the disease were included in the analyses. 
However, the null findings in respect to APOE make this unlikely. Second, it is possible that 
our older participants were too young to reveal 4-related cognitive deficits (the older group 
ranged 60 to 72 years between Waves 1 and 3). Plans are in place to collect a fourth wave of 
data that will inform this possibility in the near future. Similarly, it is likely that the youngest 
group was too old to detect any effects relating to the 2 allele. For example, a study 
reporting visuospatial deficits among 2 carriers tested school-aged children (24), whereas 
the present study assessed young adults. Additionally, in such large-scale population-based 
studies, the need for brief but comprehensive assessment of a range of cognitive abilities is a 
major consideration. It is possible, of course, that studies using alternative measures of 
memory, and assessment of other cognitive domains such as visuospatial skills and direct 
measures of executive function, may produce different outcomes. Finally, although not a 
limitation, the sample had higher educational attainment than their peers of comparable age in 
other parts of Australia. However, typical patterns of educational attainment are well 
represented in the sample. Importantly though, educational attainment more closely 
approximates that of younger individuals who are currently entering the older age ranges 
studied by the PATH Through Life Study. In this respect, the sample may have greater 
relevance to current and future aging than many other studies. 
To conclude, in this longitudinal population-based study of cognitively normal adults in their 
early 20s, 40s and 60s at baseline, we found no evidence of cognitive change as a function of 
APOE genotype. The findings suggest that (a) where it is found, 4-related cognitive decline 
in older adults is related to the preclinical phase of, as yet, undetected disease in persons 
genetically vulnerable to dementia, and (b) that the proposal of a pleiotropic association 
between the 4 allele and cognition across the ages 20 to 72 years is premature, as are 
proposals that the reverse effect may operate in relation to the 2 allele. The results clearly 
suggest that in the absence of dementia-related neuropathology, APOE genotype does not 
affect cognitive change in early, middle or late adulthood. 
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